Prospective Study
Copyright ©The Author(s) 2016.
World J Hepatol. Jul 8, 2016; 8(19): 815-824
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.815
Figure 3
Figure 3 Evolution of plasmatic neutrophil gelatinase associated lipocalin (A) and estimated glomerular filtration rate (B) during the first 12 wk of hepatitis C virus therapy with directly acting antiviral containing regimens. eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

  • Citation: Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824
  • URL: https://www.wjgnet.com/1948-5182/full/v8/i19/815.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v8.i19.815